Effect of atorvastatin on serum periostin and blood eosinophils in asthma – a placebo-controlled randomized clinical trial

Objective To investigate the effect of atorvastatin on serum periostin level and blood eosinophil count in patients with asthma. Methods Patients diagnosed with asthma were enrolled and randomised into an intervention or placebo group, to receive 40 mg atorvastatin or similar placebo, daily, for 8 weeks. Spirometry was performed at baseline, and at the end of weeks 4 and 8; patients also provided blood samples and completed an asthma control test (ACT) at baseline and at the end of week 8. Primary study outcomes were blood eosinophil count and serum periostin levels. Results Eighty patients completed the study (40 per group). Mean ACT scores were similar between the intervention and placebo groups at baseline (17.95 ± 3.75 versus 17.98 ± 3.77, respectively), and improved in the intervention group (19.88 ± 3.28), but remained unchanged in the placebo group (18.6 ± 3.26) during the treatment period. No statistically significant differences in spirometric changes, blood eosinophil count or serum periostin levels were observed between the groups during the treatment period. Conclusion Spirometric parameters and inflammatory markers did not change significantly in response to atorvastatin treatment, and did not differ between the placebo and intervention groups.

Download Full-text

Increased Serum Periostin Levels and Eosinophils in Nasal Polyps Are Associated with the Preventive Effect of Endoscopic Sinus Surgery for Asthma Exacerbations in Chronic Rhinosinusitis Patients

International Archives of Allergy and Immunology ◽

10.1159/000509253 ◽

2020 ◽

Vol 181 (11) ◽

pp. 862-870

Author(s):

Yoshihiro Kanemitsu ◽

Ryota Kurokawa ◽

Junya Ono ◽

Kensuke Fukumitsu ◽

Norihisa Takeda ◽

...

Keyword(s):

Chronic Rhinosinusitis ◽

Endoscopic Sinus Surgery ◽

Eosinophil Count ◽

Nasal Polyps ◽

Sinus Surgery ◽

Blood Eosinophil ◽

Preventive Effect ◽

Blood Eosinophil Count ◽

Asthma Exacerbations ◽

Serum Periostin

Background: Eosinophilic nasal polyps (NPs) are associated with the presence of asthma in chronic rhinosinusitis (CRS) patients. Serum periostin has been considered a relevant biomarker for unified airway diseases. Objective: To determine the utility of biomarkers including serum periostin that reflects reduction of exacerbations of comorbid asthma in CRS patients. Methods: We prospectively recruited 56 CRS patients who were subjected to undergo endoscopic sinus surgery (ESS) (20 with asthma) between October 2015 and December 2017 and followed them for 1 year after ESS. Blood eosinophil count, serum periostin, and fractional nitric oxide (FeNO) were measured at enrollment. How these type 2-driven biomarkers reflect comorbid asthma was determined using receiver operating characteristic (ROC) analysis. The frequency of asthma exacerbations during 1 year was counted both before and after ESS. Associations between preoperative biomarkers including eosinophils in NPs and asthma exacerbations were evaluated. Results: Blood eosinophil count, FeNO, and serum periostin levels were significantly higher in CRS patients with asthma than in those without (p < 0.01 for all) and discriminated comorbid asthma among CRS patients (p < 0.05; AUC > 0.80 for all). The increased preoperative serum periostin correlated with lower absolute number of postoperative exacerbations (ρ = −0.49, p = 0.03) and its relative reduction after ESS (ρ = 0.53, p = 0.03) in asthmatic patients. Increased eosinophils in NPs were also associated with reduced asthma exacerbations. Conclusion: Preoperative increased serum periostin and eosinophils in NPs are associated with the preventive effect of ESS for asthma exacerbations in CRS patients comorbid with asthma.

Download Full-text

Effect of Atorvastatin on Serum Levels of Periostin in Asthma - A Placebo Controlled Randomized Clinical Trial

10.21203/rs.3.rs-200525/v1 ◽

2021 ◽

Author(s):

Samrad Mehrabi ◽

Jalal Torkan ◽

Massood Hosseinzadeh

Keyword(s):

Placebo Group ◽

Asthma Control ◽

Eosinophil Count ◽

Inflammatory Markers ◽

Intervention Group ◽

Serum Levels ◽

Morbidity Rate ◽

High Morbidity ◽

Asthma Control Test ◽

High Morbidity Rate

Abstract Background: Asthma is a common pulmonary disease with a high morbidity rate. Considering the role of inflammation in the disease induction and severity, and the anti–inflammatory effect of atorvastatin, we aimed to investigate the effect of atorvastatin on serum level of periostin and eosinophil in patients with asthma, in order to introduce the usefulness of this drug on reducing the inflammation in patients with asthma.Methods: In a blinded randomized control trial, 80 patients with definite diagnosis of asthma were enrolled into the intervention or placebo group, who received 40 mg/day atorvastatin and similar placebo every day for 8 weeks. Spirometric measurements were performed and asthma control test was completed by the patients at baseline, after 4 weeks, and at the end of study (after 8 weeks). The primary outcomes of the study were serum eosinophil count and periostin levels. Results: 40 patients were analyzed in each group and their data were analyzed. Mean asthma control scores in the intervention and placebo groups were similar at baseline (17.95±3.75 vs. 17.98±3.77; P>0.05) and improved in the intervention group (19.88±3.28; P<0.001), but remained unchanged in the placebo group (18.6±3.26; P=0.09). Neither the spirometric changes, nor the serum levels of eosinophil count and periostin were significantly different between the groups (P>0.05).Conclusions: Although the intervention group had improved asthma control score after the intervention, this effect could be because of the indirect effect of atorvastatin, as the spirometric measurements and inflammatory markers did not change significantly and were not different between the placebo and intervention groups. Further studies with longer follow-ups may show changes in spirometric parameters by atorvastatin or its effect on other inflammatory markers.

Download Full-text

TriOptimize II: The Use of Blood Eosinophil Count in the Care of Patients with COPD Prescribed Single Inhaler Therapy: A Real-World View from Germany

10.1055/s-0039-3403156 ◽

2020 ◽

Author(s):

R Hövelmann ◽

S Bahari Javan ◽

K Melchior ◽

A Pfeffermann ◽

C Geßner

Keyword(s):

Real World ◽

Eosinophil Count ◽

World View ◽

Blood Eosinophil ◽

Blood Eosinophil Count

Download Full-text

Does peripheral blood eosinophil count predict lung function improvement in adult asthmatic subjects?

Annals of Allergy Asthma & Immunology ◽

10.1016/j.anai.2021.05.024 ◽

2021 ◽

Author(s):

Juçara Noeli Silva ◽

Alcides Rocha ◽

Ivani Aparecida de Souza ◽

Rodrigo Athanazio ◽

Eduardo Vieira Ponte

Keyword(s):

Lung Function ◽

Peripheral Blood ◽

Eosinophil Count ◽

Blood Eosinophil ◽

Peripheral Blood Eosinophil ◽

Blood Eosinophil Count ◽

Adult Asthmatic

Download Full-text

Point-of-care blood eosinophil count in a severe asthma clinic setting

Annals of Allergy Asthma & Immunology ◽

10.1016/j.anai.2017.05.016 ◽

2017 ◽

Vol 119 (1) ◽

pp. 16-20 ◽

Cited By ~ 14

Author(s):

Enrico Heffler ◽

Giovanni Terranova ◽

Carlo Chessari ◽

Valentina Frazzetto ◽

Claudia Crimi ◽

...

Keyword(s):

Severe Asthma ◽

Eosinophil Count ◽

Point Of Care ◽

Blood Eosinophil ◽

Blood Eosinophil Count ◽

Clinic Setting

Download Full-text

Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD

European Respiratory Journal ◽

10.1183/13993003.01659-2015 ◽

2016 ◽

Vol 47 (5) ◽

pp. 1562-1564 ◽

Cited By ~ 27

Author(s):

Florence Schleich ◽

Jean-Louis Corhay ◽

Renaud Louis

Keyword(s):

Eosinophil Count ◽

Blood Eosinophil ◽

Eosinophilic Inflammation ◽

Blood Eosinophil Count

Download Full-text

Clinical variables and protein biomarkers associated with blood eosinophil count and asthma in young adults

10.1183/13993003.congress-2021.pa3122 ◽

2021 ◽

Author(s):

Maura Kere ◽

Sophia Björkander ◽

Susanna Klevebro ◽

Maria Ödling ◽

Sandra Ekström ◽

...

Keyword(s):

Young Adults ◽

Eosinophil Count ◽

Blood Eosinophil ◽

Protein Biomarkers ◽

Blood Eosinophil Count ◽

Clinical Variables

Download Full-text

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s165909 ◽

2018 ◽

Vol Volume 13 ◽

pp. 2999-3002 ◽

Cited By ~ 7

Author(s):

Timm Greulich ◽

Sina Mager ◽

Tanja Lucke ◽

Andreas Rembert Koczulla ◽

Robert Bals ◽

...

Keyword(s):

Eosinophil Count ◽

Blood Eosinophil ◽

Longitudinal Stability ◽

Blood Eosinophil Count

Download Full-text

Evaluation of the peripheral blood eosinophil count as a predictor for fractional exhaled nitric oxide or bronchodilator reversibility test outcome

Allergy and Asthma Proceedings ◽

10.2500/aap.2021.42.210016 ◽

2021 ◽

Vol 42 (3) ◽

pp. 228-234

Author(s):

Bo Zhao ◽

Haiming Zheng ◽

Xiaopan Li ◽

Rui Zheng

Keyword(s):

Nitric Oxide ◽

Roc Curve ◽

Peripheral Blood ◽

Eosinophil Count ◽

Blood Eosinophil ◽

Test Results ◽

Fractional Exhaled Nitric Oxide ◽

Peripheral Blood Eosinophil ◽

Blood Eosinophil Count ◽

Feno Level

Objective: This study aimed to explore the usefulness of the peripheral blood eosinophil count (PBEC) in assessing the level of fractional exhaled nitric oxide (FeNO) and predicting bronchodilation test results. Methods: We retrospectively analyzed the data of 384 outpatients who underwent FeNO measurement at our Department of Respiratory and Critical Care Medicine from March to June 2019. The FeNO level was compared among different PBECs to explore the association among them. Furthermore, the sensitivity and specificity of PBECs in predicting bronchodilation test results were assessed by using receiver operating characteristic (ROC) curve analysis. Results: There was a moderate correlation between PBECs and FeNO levels (r = 0.414; p < 0.05). In the subjects with PBECs ≥ 0.3 × 109/L, the median FeNO level was 39 ppb (interquartile range, 22.5‐65.5 ppb), significantly higher than in the subjects with PBECs < 0.3 × 109/L. The area under the ROC curve was 0.707 (p < 0.05). The maximum Youden index (0.348) was at PBECs = 0.205 × 109/L, which achieved sensitivity and specificity of 63% and 71.8%, respectively. Conclusion: PBECs ≥ 0.3 × 109/L can predict a positive bronchodilation test result and a high FeNO level, with a probability of 50% in the subjects with chronic cough and shortness of breath; in the absence of corresponding symptoms and a low PBEC, the predictive value was small. For hospitals not able to conduct FeNO measurements, for outpatients with poor economic conditions, and for patients with confirmed or suspected novel coronavirus disease 2019, the PBEC, in conjunction with a patient's clinical symptoms, can improve the diagnostic accuracy of allergic asthma and assessment of airway inflammation while reducing the risk of infection.

Download Full-text